Alzheimer鈥檚: 鈥楾urning point鈥� in fight against disease as drug found to slow decline by up to 35%
18 July 2023
Professor Sir John Hardy (UCL Queen Square Institute of Neurology) said, "The successful outcome of the Eli Lilly鈥檚 anti-amyloid antibody donanemab is great news for Alzheimer鈥檚 disease and confirms the positive and similar outcome for Eisai鈥檚 lecanemab trial late last year".
Close
